{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T16:01:12Z","timestamp":1767542472083,"version":"3.48.0"},"reference-count":30,"publisher":"Akademiai Kiado Zrt.","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,1,4]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    Az \u0151rszemnyirokcsom\u00f3-biopszia rutinelj\u00e1r\u00e1ss\u00e1 v\u00e1lt az\n                    eml\u0151r\u00e1kos betegek kezel\u00e9s\u00e9ben. A neoadjuv\u00e1ns ter\u00e1pi\u00e1ban r\u00e9szes\u00fcl\u0151 p\u00e1ciensek egy\n                    r\u00e9sz\u00e9ben, az indul\u00e1skor klinikailag pozit\u00edv nyirokcsom\u00f3 (cN1) a kezel\u00e9s hat\u00e1s\u00e1ra\n                    klinikailag negat\u00edvv\u00e1 v\u00e1lhat (ycN0), ilyenkor az \u0151rszemnyirokcsom\u00f3-biopszia\n                    alkalmaz\u00e1sa megk\u00e9rd\u0151jelezhet\u0151 a m\u00f3dszer jelent\u0151s, &gt;10% fals negat\u00edv ar\u00e1nya\n                    miatt.\n                    <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n                    Annak vizsg\u00e1lata, hogy ebb\u0151l a helyzetb\u0151l\n                    lehet-e ki\u00fat a c\u00e9lzott h\u00f3nalji seb\u00e9szet alkalmaz\u00e1sa, amely az\n                    \u0151rszemnyirokcsom\u00f3-biopszi\u00e1t eg\u00e9sz\u00edti ki a neoadjuv\u00e1ns ter\u00e1pia el\u0151tt megjel\u00f6lt,\n                    eredetileg \u00e1tt\u00e9tes nyirokcsom\u00f3 biopszi\u00e1j\u00e1val.\n                    <jats:italic>M\u00f3dszer:<\/jats:italic>\n                    2023.\n                    06. 20. \u00e9s 2024. 11. 06. k\u00f6z\u00f6tt 18 esetben alkalmaztunk SAVI SCOUT\n                    <jats:sup>\u00ae<\/jats:sup>\n                    radarreflektoros lokaliz\u00e1ci\u00f3t cT1\u2013cT2cN1cM0 status\u00fa eml\u0151r\u00e1kos betegekn\u00e9l. Az\n                    \u0151rszemnyirokcsom\u00f3-biopszi\u00e1t kett\u0151s jel\u00f6l\u00e9ssel, az eredetileg \u00e1tt\u00e9tes nyirokcsom\u00f3\n                    biopszi\u00e1j\u00e1t SAVI SCOUT\n                    <jats:sup>\u00ae<\/jats:sup>\n                    rendszerrel v\u00e9gezt\u00fck. Amennyiben neoadjuv\u00e1ns\n                    ter\u00e1pia ut\u00e1n cN1\u2192ycN0 konverzi\u00f3 k\u00f6vetkezett be, akkor c\u00e9lzott h\u00f3nalji seb\u00e9szet\n                    t\u00f6rt\u00e9nt. Amikor nem igazol\u00f3dott \u00e1tt\u00e9t az elt\u00e1vol\u00edtott nyirokcsom\u00f3kban, akkor nem\n                    t\u00f6rt\u00e9nt tov\u00e1bbi h\u00f3nalji seb\u00e9szeti kezel\u00e9s; ha a sz\u00f6vettani vizsg\u00e1latkor mikro-\n                    vagy makrometaszt\u00e1zis igazol\u00f3dott, akkor h\u00f3nalji blokkdissecti\u00f3t v\u00e9gezt\u00fcnk.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    18 betegn\u00e9l t\u00f6rt\u00e9nt a neoadjuv\u00e1ns ter\u00e1pia el\u0151tt\n                    cN1-es nyirokcsom\u00f3 jel\u00f6l\u00e9se. 10 esetben m\u00e1r megt\u00f6rt\u00e9nt a m\u0171t\u00e9t: 1 esetben\n                    neoadjuv\u00e1ns ter\u00e1pia ut\u00e1n cN1\u2192ycN1 status maradt, ekkor h\u00f3nalji\n                    nyirokcsom\u00f3-dissecti\u00f3t v\u00e9gezt\u00fcnk; 9 betegn\u00e9l t\u00f6rt\u00e9nt neoadjuv\u00e1ns ter\u00e1pia ut\u00e1n\n                    cN1\u2192ycN0 v\u00e1ltoz\u00e1s, ekkor c\u00e9lzott h\u00f3nalji seb\u00e9szeti beavatkoz\u00e1s t\u00f6rt\u00e9nt. A jel\u00f6lt\n                    nyirokcsom\u00f3kat minden esetben siker\u00fclt azonos\u00edtani (100%). 4 esetben nem volt\n                    sz\u00fcks\u00e9g h\u00f3nalji nyirokcsom\u00f3-dissecti\u00f3ra, 2 esetben patol\u00f3giai komplett v\u00e1lasz\n                    igazol\u00f3dott. A fennmarad\u00f3 5 betegn\u00e9l mikro- vagy makrometaszt\u00e1zis igazol\u00f3dott,\n                    ez\u00e9rt h\u00f3nalji nyirokcsom\u00f3-dissectio t\u00f6rt\u00e9nt. A c\u00e9lzott h\u00f3nalji seb\u00e9szet\n                    alkalmaz\u00e1sa sor\u00e1n sz\u00f6v\u0151dm\u00e9nyt nem \u00e9szlelt\u00fcnk.\n                    <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    A\n                    SAVI SCOUT\n                    <jats:sup>\u00ae<\/jats:sup>\n                    radarreflektoros lokaliz\u00e1ci\u00f3 biztons\u00e1ggal kivitelezhet\u0151\n                    elj\u00e1r\u00e1s, lehet\u0151v\u00e9 teszi a neoadjuv\u00e1ns ter\u00e1pia el\u0151tt megjel\u00f6lt metasztatikus\n                    nyirokcsom\u00f3 elt\u00e1vol\u00edt\u00e1s\u00e1t. A c\u00e9lzott h\u00f3nalji seb\u00e9szet pontos \u00e9s biztons\u00e1gos\n                    staging m\u00f3dszernek bizonyult, amely seg\u00edthet a h\u00f3nalji nyirokcsom\u00f3-dissectio\n                    elker\u00fcl\u00e9s\u00e9ben \u00e9s a seb\u00e9szi morbidit\u00e1s cs\u00f6kkent\u00e9s\u00e9ben. Orv Hetil. 2026; 167(1):\n                    2\u20138.\n                  <\/jats:p>","DOI":"10.1556\/650.2026.33449","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T15:57:42Z","timestamp":1767542262000},"page":"2-8","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["A c\u00e9lzott h\u00f3nalji seb\u00e9szet szerepe az eml\u0151r\u00e1kos betegek kezel\u00e9s\u00e9ben SAVI SCOUT\u00ae radarlokaliz\u00e1ci\u00f3s technik\u00e1val"],"prefix":"10.1556","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-6024","authenticated-orcid":true,"given":"R\u00f3bert","family":"Mar\u00e1z","sequence":"first","affiliation":[{"name":"B\u00e1cs-Kiskun V\u00e1rmegyei Oktat\u00f3k\u00f3rh\u00e1z, \u00c1ltal\u00e1nos Seb\u00e9szeti Oszt\u00e1ly Kecskem\u00e9t, Ny\u00edri \u00fat 38., 6000 Magyarorsz\u00e1g"},{"name":"B\u00e1cs-Kiskun V\u00e1rmegyei Oktat\u00f3k\u00f3rh\u00e1z, Onkoradiol\u00f3giai K\u00f6zpont Kecskem\u00e9t Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"B\u00e1cs-Kiskun V\u00e1rmegyei Oktat\u00f3k\u00f3rh\u00e1z, \u00c1ltal\u00e1nos Seb\u00e9szeti Oszt\u00e1ly Kecskem\u00e9t, Ny\u00edri \u00fat 38., 6000 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Venczel","sequence":"additional","affiliation":[{"name":"B\u00e1cs-Kiskun V\u00e1rmegyei Oktat\u00f3k\u00f3rh\u00e1z, \u00c1ltal\u00e1nos Seb\u00e9szeti Oszt\u00e1ly Kecskem\u00e9t, Ny\u00edri \u00fat 38., 6000 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Sikorszki","sequence":"additional","affiliation":[{"name":"B\u00e1cs-Kiskun V\u00e1rmegyei Oktat\u00f3k\u00f3rh\u00e1z, \u00c1ltal\u00e1nos Seb\u00e9szeti Oszt\u00e1ly Kecskem\u00e9t, Ny\u00edri \u00fat 38., 6000 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9va","family":"Ambr\u00f3zay","sequence":"additional","affiliation":[{"name":"MaMMa Eg\u00e9szs\u00e9g\u00fcgyi Zrt., Kecskem\u00e9ti Centrum Kecskem\u00e9t Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Serf\u0151z\u0151","sequence":"additional","affiliation":[{"name":"MaMMa Eg\u00e9szs\u00e9g\u00fcgyi Zrt., Kecskem\u00e9ti Centrum Kecskem\u00e9t Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"B\u00e1cs-Kiskun V\u00e1rmegyei Oktat\u00f3k\u00f3rh\u00e1z, Onkoradiol\u00f3giai K\u00f6zpont Kecskem\u00e9t Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Kocsis","sequence":"additional","affiliation":[{"name":"B\u00e1cs-Kiskun V\u00e1rmegyei Oktat\u00f3k\u00f3rh\u00e1z, Onkoradiol\u00f3giai K\u00f6zpont Kecskem\u00e9t Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Cserni","sequence":"additional","affiliation":[{"name":"B\u00e1cs-Kiskun V\u00e1rmegyei Oktat\u00f3k\u00f3rh\u00e1z, Patol\u00f3giai Oszt\u00e1ly Kecskem\u00e9t Magyarorsz\u00e1g"},{"name":"Szegedi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Patol\u00f3giai Int\u00e9zet Szeged Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Belicza \u00c9, Surj\u00e1n C, Dombr\u00e1di V, et al. The effectiveness of the\n                    Hungarian mammography screening program. A retrospective follow-up study based\n                    on patient visit data between 2010 and 2021. [A hazai mammogr\u00e1fi\u00e1s sz\u0171r\u0151program\n                    eredm\u00e9nyess\u00e9ge. Retrospekt\u00edv k\u00f6vet\u00e9ses vizsg\u00e1lat a betegforgalmi adatok alapj\u00e1n\n                    2010 \u00e9s 2021 k\u00f6z\u00f6tt.] Orv Hetil. 2025; 166: 1689-1705. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2025.33400","DOI":"10.1556\/650.2025.33400"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Kenessey I, Szil\u00e1gyi I, Dobozi M, et al. The role of National Cancer\n                    Registry in the assessment of Hungarian cancer epidemiology. [A Nemzeti\n                    R\u00e1kregiszter szerepe a hazai daganatos epidemiol\u00f3giai helyzet felm\u00e9r\u00e9s\u00e9ben.] Orv\n                    Hetil. 2024; 165: 925-932. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2024.33062","DOI":"10.1556\/650.2024.33062"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter\n                    trial of sentinel node biopsy versus standard axillary treatment in operable\n                    breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98: 599-609.\n                        https:\/\/doi.org\/10.1093\/jnci\/djj158","DOI":"10.1093\/jnci\/djj158"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel lymph node\n                    biopsy for patients with early-stage breast cancer: American Society of Clinical\n                    Oncology Clinical Practice Guideline update. J Clin Oncol. 2017; 35: 561-564.\n                        https:\/\/doi.org\/10.1200\/JCO.2016.71.0947","DOI":"10.1200\/JCO.2016.71.0947"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no\n                    axillary dissection in women with invasive breast cancer and sentinel-node\n                    metastasis: a randomized clinical trial. JAMA 2011; 305: 569-575.\n                        https:\/\/doi.org\/10.1001\/jama.2011.90","DOI":"10.1001\/jama.2011.90"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or\n                    surgery of the axilla after a positive sentinel node in breast cancer (EORTC\n                    10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3\n                    non-inferiority trial. Lancet Oncol. 2014; 15: 1303-1310.\n                        https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7","DOI":"10.1016\/S1470-2045(14)70460-7"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"S\u00e1volt \u00c1, P\u00e9ley G, Polg\u00e1r C, et al. Eight-year follow up result of\n                    the OTOASOR trial: the optimal treatment of the axilla - Surgery or radiotherapy\n                    after positive sentinel lymph node biopsy in early-stage breast cancer: a\n                    randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol.\n                    2017; 43: 672-679.\n                    https:\/\/doi.org\/10.1016\/j.ejso.2016.12.011","DOI":"10.1016\/j.ejso.2016.12.011"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after\n                    neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN\n                    FNAC study. J Clin Oncol. 2015; 33: 258-264.\n                        https:\/\/doi.org\/10.1200\/JCO.2014.55.7827","DOI":"10.1200\/JCO.2014.55.7827"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary\n                    evaluation following neoadjuvant therapy for patients with node-positive breast\n                    cancer using selective evaluation of clipped nodes: implementation of targeted\n                    axillary dissection. J Clin Oncol. 2016; 34: 1072-1078.\n                        https:\/\/doi.org\/10.1200\/JCO.2015.64.0094","DOI":"10.1200\/JCO.2015.64.0094"},{"key":"R10","unstructured":"L\u00e1z\u00e1r G, K\u00f3sa C, Mar\u00e1z R, et al. Modern surgical treatment of breast\n                    cancer. 5th Breast Cancer Consensus Conference. [V. Eml\u0151r\u00e1k Konszenzus\n                    Konferencia - Az eml\u0151r\u00e1k korszer\u0171 seb\u00e9szi kezel\u00e9se.] Magy Onkol. 2025; 69:\n                    276-295. [Hungarian]"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Moo TA, Edelweiss M, Hajiyeva S, et al. Is magnetic seed\n                    localization a reliable method for targeted axillary dissection after\n                    neoadjuvant chemotherapy? Ann Surg Oncol. 2020; 27: 3513-3518.\n                        https:\/\/doi.org\/10.1245\/s10434-020-08273-4","DOI":"10.1245\/s10434-020-08273-4"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Gera R, Tayeh S, Al-Reefy S, et al. Evolving role of targeted\n                    axillary dissection in breast cancer management: a systematic review. Anticancer\n                    Res. 2020; 40: 2239-2245.\n                    https:\/\/doi.org\/10.21873\/anticanres.14135","DOI":"10.21873\/anticanres.14135"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Switalla KM, Boughey JC, Dimitroff K, et al. Clipping the positive\n                    lymph node in patients with clinically node-positive breast cancer treated with\n                    neoadjuvant chemotherapy: impact on axillary surgery in the ISPY-2 clinical\n                    trial. Ann Surg Oncol. 2024; 31: 7249-7259.\n                        https:\/\/doi.org\/10.1245\/s10434-024-15792-x","DOI":"10.1245\/s10434-024-15792-x"},{"key":"R14","unstructured":"Simons JM, van Nijnatten TJ, van der Pol CC, et al. Diagnostic\n                    accuracy of different marking techniques for the localization of axillary lymph\n                    nodes in breast cancer patients after neoadjuvant systemic therapy: a systematic\n                    review and meta-analysis. Ann Surg. 2022; 275: 303-311."},{"key":"R15","unstructured":"El Hage Chehade H, Headon H, El Tokhy O, et al. Is targeted axillary\n                    dissection the new standard of care in node-positive breast cancer patients\n                    treated with neoadjuvant chemotherapy? A systematic review and meta-analysis of\n                    the literature. World J Surg Oncol. 2016; 14: 145."},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response\n                    and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.\n                    Lancet 2014; 384: 164-172.\n                        https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"R17","unstructured":"Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab\n                    in combination with standard neoadjuvant chemotherapy in HER2-positive breast\n                    cancer: the TRYPHAENA study. Ann Oncol. 2018; 29: 2328-2336."},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Venczel L, Mar\u00e1z R, Ambr\u00f3zay \u00c9, et al. The role of indocyanine green\n                    fluorescence in sentinel lymph node biopsy for breast cancer. [Az\n                    indoci\u00e1nz\u00f6ld-fluoreszcencia hasznos\u00edt\u00e1sa az eml\u0151r\u00e1k miatt v\u00e9gzett\n                    \u0151rszemnyirokcsom\u00f3-biopszi\u00e1ban.] Orv Hetil. 2021; 162: 293-297. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2021.31994","DOI":"10.1556\/650.2021.31994"},{"key":"R19","unstructured":"Cserni G, Papp E, J\u00e1ray B, et al. Pathological diagnosis, work-up\n                    and reporting of breast cancer. Recommendations of the 5th Hungarian Consensus\n                    Conference on Breast Cancer. [Az eml\u0151r\u00e1k patol\u00f3giai diagnosztik\u00e1ja, feldolgoz\u00e1sa\n                    \u00e9s k\u00f3rsz\u00f6vettani leletez\u00e9se. Szakmai \u00fatmutat\u00e1s a V. Eml\u0151r\u00e1k Konszenzus\n                    Konferencia alapj\u00e1n.] Magy Onkol. 2025; 69: 243-274.\n                    [Hungarian]"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for\n                    patients with early-stage breast cancer: American Society of Clinical Oncology\n                    clinical practice guideline. J Clin Oncol. 2014; 32: 1365-1383.\n                        https:\/\/doi.org\/10.1200\/JCO.2013.54.1177","DOI":"10.1200\/JCO.2013.54.1177"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after\n                    sentinel lymph node biopsy in primary breast cancer: results from a randomized\n                    controlled trial. J Clin Oncol. 2005; 23: 4312-4321.\n                        https:\/\/doi.org\/10.1200\/JCO.2005.03.228","DOI":"10.1200\/JCO.2005.03.228"},{"key":"R22","unstructured":"El Hage Chehade H, Headon H, Heeney J, et al. The role of targeted\n                    axillary dissection in node-positive breast cancer: a systematic review. Ann\n                    Surg Oncol. 2021; 28: 5669-5683."},{"key":"R23","unstructured":"Mango VL, Wynn RT, Feldman S, et al. SCOUT radar localization system\n                    for breast cancer: how to and initial experience. Clin Imaging 2019; 55:\n                    33-39."},{"key":"R24","unstructured":"El Hage Chehade H, Heeney J, Pratt G, et al. Targeted axillary\n                    dissection for node-positive breast cancer after neoadjuvant chemotherapy:\n                    current evidence and clinical implications. Cancers (Basel) 2024; 16:\n                    1345."},{"key":"R25","unstructured":"Park KU, Caudle AS, Black DM, et al. Wireless nonradioactive\n                    surgical localization of nonpalpable breast lesions: a prospective trial. Ann\n                    Surg Oncol. 2020; 27: 3540-3546."},{"key":"R26","unstructured":"Hartmann S, Reimer T, Gerber B. Targeted axillary dissection (TAD)\n                    improves the diagnostic accuracy of axillary staging after neoadjuvant\n                    chemotherapy in node-positive breast cancer. Breast 2020; 49:\n                    115-120."},{"key":"R27","unstructured":"Diepstraten SC, van der Wal -BC, Rutgers EJ, et al. Long-term\n                    complications of axillary lymph node dissection compared to sentinel lymph node\n                    biopsy in breast cancer patients. Ann Surg Oncol. 2011; 18:\n                    94-101."},{"key":"R28","unstructured":"Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and\n                    resection of clipped node decrease the false-negative rate of sentinel lymph\n                    node surgery in patients presenting with node-positive breast cancer (TAD\n                    study). Ann Surg. 2016; 264: 430-436."},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact\n                    of pathologic complete response on prognosis after neoadjuvant chemotherapy in\n                    various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30: 1796-1804.\n                        https:\/\/doi.org\/10.1200\/JCO.2011.38.8595","DOI":"10.1200\/JCO.2011.38.8595"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in\n                    patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA):\n                    a prospective, multicentre cohort study. Lancet Oncol. 2013; 14: 609-618.\n                        https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9","DOI":"10.1016\/S1470-2045(13)70166-9"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/167\/1\/article-p2.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/167\/1\/article-p2.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/167\/1\/article-p2.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T15:57:50Z","timestamp":1767542270000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/167\/1\/article-p2.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":30,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33449","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]}}}